Windtree Therapeutics, Inc. engages in the manufacture and development of products for infants and respiratory diseases. It focuses on producing of surfactant replacement therapies for patients with respiratory disease and neonatology for the improvement of respiratory distress syndrome for infants. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.